Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens

Abstract

The choline uptake pattern corresponded to the histological localization of prostate cancer in fewer than 50 % of lesions. Even when corresponding visual choline uptake was found, this uptake was highly variable between patients. Therefore SUV thresholding with standard algorithms did not lead to satisfying results with respect to defining tumour tissue in the prostate.

Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging

“…Only 46% of histopathologically positive lesions had increased 11 C-choline uptake. The authors could not determine a specific SUV threshold for distinguishing tumor tissue from nontumor tissue (20). Those results were confirmed by Grosu et al, who showed that correct differentiation of malignant from normal prostate tissue with 11 C-choline PET/CT was not feasible (21).…”

“…There was no significant difference between the SUV max of malignant changes and the SUV max of benign prostatic changes (18). Bundschuh et al correlated 11 C-choline uptake in the prostate gland with histopathologic findings after radical prostatectomy (20). Only 46% of histopathologically positive lesions had increased 11 C-choline uptake.…”

“…Target tumor volume delineation for intraprostatic lesions is critical because of the lack of an SUV threshold for the differentiation of benign from malignant tissues (20,21). Before radiation treatment planning, 11 C-or 18 F-choline PET/CT might be used in patients with high-risk PC to detect and encompass lymph node metastases outside the conventional irradiation field (for an overview, see Schwarzenböck et al (46)).…”

Current status of choline‐PET and prostate cancer

“…8 Others have reported that choline uptake corresponded to histological localisation of the tumour in fewer than 50 per cent of cases, with a great deal of interpatient variability. 9 Some have not even been able to demonstrate significant difference in 18 F-choline uptake between benign and malignant prostate lesions. 10 Currently there is not enough evidence to recommend the use of choline-PET/CT as a first-line screening procedure.…”

Androgen Deprivation Therapy (ADT), Metabolic Syndrome and Metastatic Prostate Cancer: In Vivo and In Vitro Assessments of Effects of Metformin

“…For the PET component, only focal uptake greater than background prostate uptake was classified as being PET positive. Reports were correlated with whole-mount histopathology results, with volume correction for tissue shrinkage (in vivo volume = ex vivo fixed volume x 1.3) [275]. Statistical analyses such as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated with SPSS Statistics (IBM Corp.…”